Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Nephrotic syndrome)
21,822 results
  • Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis. [Journal Article]
  • EREur Rev Med Pharmacol Sci 2018; 22(22):8021-8029
  • Zhang J, Bian L, … Lin P
  • CONCLUSIONS: Rituximab had a beneficial effect and remissions of proteinuria on MN during follow-up times, but some adverse events were still unknown. Taking consideration of long-term therapeutic side effects and dose of the drug, we suggest that rituximab might replace cyclophosphamide and steroids as first-line immunosuppressive therapy in MN patients.
  • Minimal change disease: A case report. [Journal Article]
  • NNursing 2018 Dec 10
  • Mitchell-Brown FM, Veisze T
  • Although minimal change disease (MCD) is a major cause of nephrotic syndrome in children, it's less common in adults. It develops from damage to the glomeruli with a loss of large amount of protein i...
  • SGPL1 Deficiency: A Rare Cause of Primary Adrenal Insufficiency. [Journal Article]
  • JCJ Clin Endocrinol Metab 2018 Dec 03
  • Settas N, Persky R, … Stratakis CA
  • CONCLUSIONS: New genetic causes of PAI continue to be identified. We suggest that screening for SGPL1 mutations should not be reserved only for patients with nephrotic syndrome but may also include patients with PAI that lack other clinical manifestations of NPHS14 since, in certain cases, kidney disease and accompanying features might develop later on. Timely diagnosis of this specific sphingolipidosis, while the kidneys still function normally, can lead to prompt initiation of therapy and improve outcome especially, if a targeted NPHS14-treatment is available in the future.
New Search Next